By Stephen Beech

Cancer drugs that have been around for two decades were able to eliminate aggressive tumors in a "remarkable" clinical trial.

Two patients - one with the deadliest form of skin cancer called melanoma and another with breast cancer - saw their tumors disappear completely.

American scientists showed that an engineered antibody improved the class of drugs that had struggled to make good on their early promise.

The drugs - called CD40 agonist antibodies - had initially shown great potential.

But, while effective at activating the immune system to kill cancer cells in animal models, the drugs had only "limited" impact on patients in clinical trials.

They also triggered dangerously systemic inflammatory responses, low platelet counts, and liver toxicity, among other a

See Full Page